MDMA for PTSD

The FDA is expected to approve MDMA for PTSD by the end of 2023, allowing for off-label prescriptions. A limited compassionate use program will soon enable treatment-resistant patients to access MDMA during ongoing studies. As the landscape for psychedelics evolves, parallels are drawn to the medical marijuana movement, suggesting a gradual shift towards broader access for personal growth.